Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Terminated 3Recruiting 3Active not recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Sarcoma 7Osteosarcoma 6Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma 6Testicular Neoplasms 4Burkitt Lymphoma 4Testicular Germ Cell Tumor 3Teratoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Lymphoma, B-Cell 3Carcinoma, Renal Cell 3Breast Neoplasms 3Wilms Tumor 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Ovarian Neoplasms 2Optic Nerve Glioma 2Neuroblastoma 2Neoplasms 2Medulloblastoma 2Lymphoma, Large-Cell, Anaplastic 2Lymphatic Diseases 2Liver Neoplasms 2Kidney Neoplasms 2Immunoproliferative Disorders 2Hematologic Diseases 2Fibrosarcoma 2Familial ependymoma 2Dendritic Cell Sarcoma, Interdigitating 2

Interventions

Rituximab 24Cyclophosphamide 14fludarabine 8Etoposide 6Vincristine 5Prednisone 5Doxorubicin 5fludarabine phosphate 4Carboplatin 4venetoclax 3obinutuzumab 3ibrutinib 3atezolizumab 3Whole-Body Irradiation 3Mycophenolic Acid 3Lenalidomide 3Ifosfamide 3Cytarabine 3Carmustine 3Bortezomib 3Bendamustine Hydrochloride 3ublituximab 2pembrolizumab 2pegfilgrastim 2ibritumomab tiuxetan 2Tiragolumab 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Indium 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Lymphoma, B-Cell × Ifosfamide × Clear all
NCT02592876 2019-05-17

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Seagen Inc.

Phase 2 Terminated
81 enrolled 15 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01300793 2012-09-26

V-RICE

University of California, San Francisco

Phase 1 Terminated
6 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT00515138 2012-04-12

A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant

University of California, San Francisco

Phase EARLY_PHASE1 Terminated
7 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡